Best Practice & Research Clinical Endocrinology & Metabolism
Volume 20, Issue 3 , Pages 369-384 , September 2006

Screening for primary aldosteronism

  • Martin Reincke (Professor and Head of Department)

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +49 89 5160 2100; Fax: +49 89 5160 4428.

References 

  1. Conn J. Presidential address. Part II. Primary aldosteronism, a new clinical syndrome. The Journal of Laboratory and Clinical Medicine. 1955;45:6–17
  2. Mulatero P, Dluhy R, Giacchetti G, et al. Diagnosis of primary aldosteronism: from screening to subtype differentiation. Trends in Endocrinology and Metabolism. 2005;16(3):114–119
  3. Reincke M, Seiler L, Rump LC. Normokaliämischer primärer Hyperaldosteronismus. Deutsches Ärzteblatt. 2003;100(4):A184–A190
  4. Gordon R, Klemm S, Stowasser M, et al. How common is primary aldosteronism? Is it the most frequent form of curable hypertension?. Journal of Hypertension. 1993;11(supplement 5):S310–S311
  5. Benchetrit S, Bernheim J, Podjarny E. Normokalemic hyperaldosteronism in patients with resistant hypertension. The Israel Medical Association Journal. 2002;4:17–20
  6. Wolf-Maier K, Cooper R, Banegas J, et al. Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. The Journal of the American Medical Association. 2003;289(18):2363–2369
  7. Delcayre C, Silvestre J, Garnier A, et al. Cardiac aldosterone production and ventricular remodeling. Kidney International. 2000;57:1346–1351
  8. Rocha R, Funder J. The pathophysiology of aldosterone in the cardiovascular system. Annals of the New York Academy of Sciences. 2002;970:89–100
  9. Matsumura K, Fujii K, Ioniki H, et al. Role of aldosterone in left ventricular hypertrophy in hypertension. American Journal of Hypertension. 2006;19(1):23–28
  10. Rossi G, Sacchetto A, Visentin P, et al. Changes in left ventricular anatomy and function in hypertension and primary aldosteronism. Hypertension. 1996;27:1039–1045
  11. Pitt B, Zannad F, Remme W, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. The New England Journal of Medicine. 1999;341(19):709–717
  12. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. The New England Journal of Medicine. 2003;348:1309–1321
  13. Mulatero P, Stowasser M, Loh K, et al. Increased diagnosis of primary aldosteronism including surgically correctable forms in centers from five continents. The Journal of Clinical Endocrinology and Metabolism. 2004;89:1045–1050
  14. Seiler L, Rump L, Borm K, et al. Prevalence of primary hyperaldosteronism in a university hypertension outpatient clinic: is it underdiagnosed?. Experimental and Clinical Endocrinology & Diabetes. 2002;110(supplement 1):S84
  15. Conn J, Lawrence H. Primary aldosteronism, a new clinical entity. Annals of Internal Medicine. 1956;44(1):1–15
  16. Fallo F, Veglio F, Bertello C, et al. Prevalence and characteristics of the metabolic syndrome in primary aldosteronism. The Journal of Clinical Endocrinology and Metabolism. 2006;91(2):454–499
  17. Ganguly A. Primary aldosteronism. The New England Journal of Medicine. 1998;25:1828–1834
  18. Mosso L, Carvajal C, Gonzales A, et al. Primary aldosteronism and hypertensive disease. Hypertension. 2003;42:161–165
  19. Vantyghem M, Ronci N, Provost F, et al. Aldosterone-producing adenoma without hypertension: a report of two cases. European Journal of Endocrinology. 1999;141(3):279–285
  20. Irony I, Kater CE, Biglierir EG, et al. Correctable subsets of primary aldosteronism. Primary adrenal hyperplasia and renin responsive adenoma. American Journal of Hypertension. 1990;3:576–582
  21. Stowasser M, Gordon R. Familial hyperaldosteronism. The Journal of Steroid Biochemistry and Molecular Biology. 2001;78:215–229
  22. Luton J, Cerdas S, Billaud L, et al. Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy. The New England Journal of Medicine. 1990;322(17):1195–1201
  23. Allolio B, Fassnacht M, Arlt W. Maligne Tumoren der Nebennierenrinde. Internist. 2002;43:186–195
  24. Blumenfeld J, Sealey J, Schlussel Y, et al. Diagnosis and treatment of primary hyperaldosteronism. Annals of Internal Medicine. 1994;121(11):877–885
  25. Padfield P. Prevalence and role of a raised aldosterone to renin ratio in the diagnosis of primary aldosteronism: a debate on the scientific logic of the use of the ratio in practice. Clinical Endocrinology. 2003;59:422–426
  26. Anonymous . Idiopathic aldosteronism – a diagnostic artifact?. Lancet. 1979;2:1221–1222
  27. Gordon R, Stowasser M, Klemm S, et al. Primary aldosteronism – some genetic, morphological, and biochemical aspects of subtypes. Steroids. 1995;60:35–41
  28. Fallo F, Barzon L, Biasi F, et al. Zona fasciculata-like histotype and aldosterone response to upright posture are not related in aldosterone-producing adenomas. Experimental and Clinical Endocrinology & Diabetes. 1998;106:74–78
  29. Fontes R, Kater C, Biglieri E, et al. Reassessment of the predictive value of the postural stimulation test in primary aldosteronism. American Journal of Hypertension. 1991;4:786–791
  30. Stowasser M, Gordon R, Gunasekera T, et al. High rate of detection of primary aldosteronism, including surgically treatable forms, after ‘non-selective’ screening of hypertensive patients. Journal of Hypertension. 2003;21:2149–2157
  31. Fardella C, Mosso L, Gómez-Sánchez C, et al. Primary aldosteronism in essential hypertensives: prevalence, biochemical profile, and molecular biology. The Journal of Clinical Endocrinology and Metabolism. 2000;85(5):1863–1867
  32. Lim P, Rodgers P, Cardale K, et al. Potentially high prevalence of primary aldosteronism in a primary-care population. Lancet. 1999;353:40
  33. Loh K, Koay E, Khaw M, et al. Prevalence of primary aldosteronism among Asian hypertensive patients in Singapore. The Journal of Clinical Endocrinology and Metabolism. 2000;85:2854–2859
  34. Williams J, Williams G, Raji A, et al. Prevalence of primary hyperaldosteronism in mild to moderate hypertension without hypokalaemia. Journal of Human Hypertension. 2006;20(2):129–136
  35. Plouin P, Amar L, Chatellier G. Trends in the prevalence of primary aldosteronism, aldosterone-producing adenomas, and surgically correctable aldosterone-dependent hypertension. Nephrology, Dialysis, Transplantation. 2004;19:774–777
  36. Rossi E, Regolisti G, Negro A, et al. High prevalence of primary aldosteronism using postcaptopril plasma aldosterone to renin ratio as a screening test among Italian hypertensives. American Journal of Hypertension. 2002;15:896–902
  37. Mosso L, Fardella C, Montero J, et al. High prevalence of undiagnosed primary hyperaldosteronism among patients with essential hypertension. Revista Médica de Chile. 1999;127(7):800–806
  38. Rayner B, Opie L, Davidson J. The aldosterone/renin ratio as a screening test for primary aldosteronism. South African Medical Journal. 2000;90(4):394–400
  39. Kaplan NM. The current epidemic of primary aldosteronism: causes and consequences. Journal of Hypertension. 2004;22(5):863–869
  40. Kaplan NM. The current epidemic of primary aldosteronism: causes and consequences. Journal of Hypertension. 2004;22(10):2040;[Author reply]
  41. Dluhy R, Williams G. Aldosterone – villain or bystander?. The New England Journal of Medicine. 2004;351(1):8–10
  42. Kaplan N. Cautions over the current epidemic of primary aldosteronism. Lancet. 2001;357:953–954
  43. Sywak M, Pasieka J. Long-term follow-up and cost benefit of adrenalectomy in patients with primary hyperaldosteronism. The British Journal of Surgery. 2002;89:1587–1593
  44. McKenna T, Sequeira S, Heffernan A, et al. Diagnosis under random conditions of all disorders of the renin–angiotensin–aldosterone axis, including primary aldosteronism. The Journal of Clinical Endocrinology and Metabolism. 1991;73:952–957
  45. Spence JD. The current epidemic of primary aldosteronism: causes and consequences. Journal of Hypertension. 2004;22(10):2038–2039
  46. Tiu S, Choi C, Shek C, et al. The use of aldosterone–renin ratio as a diagnostic test for primary hyperaldosteronism and its test characteristics under different conditions of blood sampling. The Journal of Clinical Endocrinology and Metabolism. 2005;90(1):72–78
  47. Hiramatsu K, Yamada T, Yukimura Y, et al. A screening test to identify aldosterone-producing adenoma by measuring plasma renin activity. Archives of Internal Medicine. 1981;141:1589–1593
  48. Lim P, MacDonald T. Primary aldosteronism, diagnosed by the aldosterone to renin ratio, is a common cause of hypertension. Clinical Endocrinology. 2003;59:427–430
  49. Gordon R. The challenge of more robust and reproducible methodology in screening for primary aldosteronism. Journal of Hypertension. 2004;22:251–255
  50. Schwartz G, Chapman A, Boerwinkle E, et al. Screening for primary aldosteronism: implications of an increased plasma aldosterone/renin ratio. Clinical Chemistry. 2002;48(11):1919–1923
  51. Schwartz G, Turner S. Screening for primary aldosteronism in essential hypertension: diagnostic accuracy of the ratio of plasma aldosterone concentration to plasma renin activity. Clinical Chemistry. 2005;51(2):386–394
  52. Connell J, Fraser R. Primary aldosteronism. In:  Wass J,  Shalet S editor. The Oxford Textbook of Endocrinology and Diabetes. Oxford: Oxford University Press; 2002;p. 791–799
  53. Seiler L, Rump L, Schulte-Mönting J, et al. Diagnosis of primary aldosteronism: value of different screening parameters and influence of antihypertensive medication. European Journal of Endocrinology. 2004;150:329–337
  54. Tanabe A, Naruse M, Takagi S, et al. Variability in the renin/aldosterone profile under random and standardized sampling conditions in primary aldosteronism. The Journal of Clinical Endocrinology and Metabolism. 2003;88(6):2489–2494
  55. Stowasser M, Gordon R. Prevalence and diagnostic workup of primary aldosteronism: new knowledge and new approaches. Nephrology. 2001;6:119–126
  56. Gallay B, Ahmad S, Xu L, et al. Screening for primary aldosteronism without discontinuing hypertensive medications: plasma aldosterone-renin ratio. American Journal of Kidney Diseases. 2001;37(4):699–705
  57. Seifarth C, Trenkel S, Schobel H, et al. Influence of antihypertensive medication on aldosterone and renin concentration in the differential diagnosis of essential hypertension and primary aldosteronism. Clinical Endocrinology. 2002;57:457–465
  58. Nadler J, Hsueh W, Horton R. Therapeutic effect of calcium channel blockade in primary aldosteronism. The Journal of Clinical Endocrinology and Metabolism. 1985;60:896–899
  59. Montori V, Young WJ. Use of plasma aldosterone concentration-to-plasma renin activity ratio as a screening test for primary aldosteronism. A systematic review of the literature. Endocrinology and Metabolism Clinics of North America. 2002;31(3):619–632
  60. Montori V, Schwartz G, Chapman A, et al. Validity of the aldosterone-renin ratio used to screen for primary aldosteronism. Mayo Clinic Proceedings. 2001;76:877–882
  61. Auchus R. Aldo is back: recent advances and unresolved controversies in hyperaldosteronism. Current Opinion in Nephrology and Hypertension. 2003;12(2):153–158
  62. Cartledge S, Lawson N. Aldosterone and renin measurements. Annals of Clinical Biochemistry. 2000;37:262–278
  63. Sealey JE, Blumenfeld J, Laragh JH. Prorenin cryoactivation as a possible cause of normal renin levels in patients with primary aldosteronism. Journal of Hypertension. 2005;23(2):459–460
  64. Perschel F, Schemer R, Seiler L, et al. Rapid screening test for primary aldosteronism: ratio of plasma aldosterone to renin concentration determined by fully automated chemiluminescence immunoassays. Clinical Chemistry. 2004;50(9):1650–1655
  65. Brown M, Cramp H, Zammit V, et al. Primary hyperaldosteronism: a missed diagnosis in ‘essential hypertensives’?. Australian and New Zealand Journal of Medicine. 1996;4:533–538
  66. Trenkel S, Seifarth C, Schobel H, et al. Ratio of serum aldosterone to plasma renin concentration in essential hypertension and primary aldosteronism. Experimental and Clinical Endocrinology & Diabetes. 2002;110:80–85
  67. Olivieri O, Ciacciarelli A, Signorelli D, et al. Aldosterone to renin ratio in a primary care setting: the bussolengo study. The Journal of Clinical Endocrinology and Metabolism. 2004;89:4221–4226
  68. Ferrari P, Shaw S, Nicod J, et al. Active renin versus plasma renin activity to define aldosterone-to-renin ratio for primary aldosteronism. Journal of Hypertension. 2004;22:377–381
  69. Unger N, Lopez Schmidt I, Pitt C. Comparison of active renin concentration and plasma renin activity for the diagnosis of primary hyperaldosteronism in patients with an adrenal mass. European Journal of Endocrinology. 2004;150:517–523
  70. Mantero F, Bedendo O, Opocher G. Does dynamic testing have a place in the modern assessment of endocrine hypertension?. Journal of Endocrinological Investigation. 2003;26(supplement 7):92–98
  71. Stowasser M, Gordon R, Rutherford J, et al. Diagnosis and management of primary aldosteronism. Journal of the Renin-Angiotensin-Aldosterone System. 2001;2:156–169
  72. Kem D, Weinberger M, Mayes D, et al. Saline suppression of plasma aldosterone in hypertension. Archives of Internal Medicine. 1971;128:380–386
  73. Holland O, Brown H, von Kuhnert L, et al. Further evaluation of saline infusion for the diagnosis of primary aldosteronism. Hypertension. 1984;6:717–723
  74. Corvol P, Houde M, Benguigui L, et al. Le système rénine-angiotensine-aldostérone chez les sujets hypertendus. II. Le diagnostic de l'hyperaldostéronisme primaire. La Nouvelle Presse Médicale. 1977;6(29):2569–2572
  75. Gordon RD, Taylor WL, Rossetti TR et al. A prospective evaluation of definite tests for primary aldosteronism. 21st Annual Scientific Meeting, Melbourne Exhibition Centre, December 9–11, 1999. Program and Abstracts, published by High Blood Pressure Research Council of Australia Inc. ISSN 1329-105X.
  76. Schirpenbach C, Seiler L, Maser-Gluth C, et al. Confirmatory testing in normokalaemic primary aldosteronism: the value of saline infusion test and urinary aldosterone metabolites. European Journal of Endocrinology. 2006;154(6):865–873
  77. Young W. Primary aldosteronism. Annals of the New York Academy of Sciences. 2002;970:61–76
  78. Bravo E, Tarazi R, Dustan H, et al. The changing clinical spectrum of primary aldosteronism. American Journal of Medicine. 1983;74:641–651
  79. Agharazii M, Douville P, Grose J, et al. Captopril suppression versus salt loading in confirming primary aldosteronism. Hypertension. 2001;37:1440–1443
  80. Castro O, Yu X, Kern D. Diagnostic value of the post-Captopril test in primary aldosteronism. Hypertension. 2002;39:935–938
  81. Abdelhamid S, Blomer R, Hommel G, et al. Urinary tetrahydroaldosterone as a screening method for primary aldosteronism: a comparative study. American Journal of Hypertension. 2003;16:522–530
  82. Gomez-Sanchez C, Holland O. Urinary tetrahydroaldosterone and aldosterone-18-glucuronide excretion in white and black normal subjects and hypertensive patients. The Journal of Clinical Endocrinology and Metabolism. 1981;52:214–219
  83. Schirpenbach C, Seiler L, Maser-Gluth C, et al. Automated chemiluminescence-immunoassay for aldosterone during dynamic testing: comparison to radioimmunoassays with and without extraction steps. Clinical Chemistry. 2006;20:[Epub ahead of print]
  84. Lingam R, Sohaib S, Vlahos I, et al. CT of primary hyperaldosteronism (Conn's syndrome): the value of measuring the adrenal gland. American Journal of Roentgenology. 2003;181:843–849
  85. Guest P. Adrenal imaging. In:  Wass J,  Shalet S editor. The Oxford Textbook of Endocrinology and Diabetes. Oxford: Oxford University Press; 2002;p. 747–756
  86. Lingam R, Sohaib S, Rockall A, et al. Diagnostic performance of CT versus MR in detecting aldosterone-producing adenoma in primary hyperaldosteronism (Conn's syndrome). European Radiology. 2004;14(10):1787–1792
  87. Young W, Stanson A, Thompson G, et al. Role for adrenal venous sampling in primary aldosteronism. Surgery. 2004;136(6):1227–1235
  88. Magill S, Raff H, Shaker J, et al. Comparison of adrenal vein sampling and computed tomography in the differentiation of primary aldosteronism. The Journal of Clinical Endocrinology and Metabolism. 2001;86:1066–1071
  89. Stowasser M, Gordon R. Primary aldosteronism: learning from the study of familial varieties. Journal of Hypertension. 2000;18:1165–1176
  90. Kann P, Hengstermann C, Heussel C, et al. Endosonography of the adrenal glands: normal size – pathological findings. Experimental and Clinical Endocrinology & Diabetes. 1998;106(2):123–129
  91. Kann P. Endoscopic ultrasound imaging of the adrenals. Endoscopy. 2005;37(3):244–253
  92. Vallotton M. Primary aldosteronism. Part II differential diagnosis of primary hyperaldosteronism and pseudoaldosteronism. Clinical Endocrinology. 1996;45:53–60
  93. Radin D, Manoogian C, Nadler J. Diagnosis of primary hyperaldosteronism: importance of correlating CT findings with endocrinologic studies. American Journal of Roentgenology. 1992;158(3):553–557
  94. Sheaves R, Goldin J, Reznek R, et al. Relative value of computed tomography scanning and venous sampling in establishing the cause of primary aldosteronism. European Journal of Endocrinology. 1996;134(3):308–313
  95. Phillips J, Walther M, Pezzullo J, et al. Predictive value of preoperative tests in discriminating bilateral hyperplasia from an aldosterone-producing adenoma. The Journal of Clinical Endocrinology and Metabolism. 2000;85(12):4526–4533
  96. Doppman J, Gill J. Hyperaldosteronism: sampling the adrenal veins. Radiology. 1996;198:309–312
  97. Young W, Stanson A, Grant C, et al. Primary aldosteronism: adrenal venous sampling. Surgery. 1996;120:913–920
  98. Rossi G, Sacchetto A, Chiesura-Corona M, et al. Identification of the etiology of primary aldosteronism with adrenal vein sampling in patients with equivocal computed tomography and manetic resonance findings: results in 104 consecutive cases. The Journal of Clinical Endocrinology and Metabolism. 2001;86:1083–1090
  99. Lyons D, Kem D, Brown R, et al. Single dose captopril as a diagnostic test for primary aldosteronism. The Journal of Clinical Endocrinology and Metabolism. 1983;57:892–896

PII: S1521-690X(06)00054-6

doi: 10.1016/j.beem.2006.07.007

Best Practice & Research Clinical Endocrinology & Metabolism
Volume 20, Issue 3 , Pages 369-384 , September 2006

Article Tools

* Image Usage & Resolution